Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.

By P. O'Byrne, H. Bisgaard, P. Godard, M. Pistolesi, M. Palmqvist, Yuan-jue Zhu, T. Ekström, E. Bateman. American Journal of Respiratory and Critical Care Medicine, 2005

628 citations recorded by the source corpus.

Subfields: Immunology and Allergy, Physiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/6590777262dd967eb85752ec513415dff5141a32

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. H. Reddel
2. E. D. Bateman
3. H. Kerstjens
4. M. Vareille
5. L. Boulet
6. E. Kieninger
7. P. Chanez
8. M. Partridge

Citations in the corpus

• The Airway Epithelium: Soldier in the Fight against Respiratory Viruses (2011, background): “Also of note is the recognized disappointing or incomplete protection of steroid-based therapies in asthma exacerbations (64, 197, 295) which are of viral etiology.”
• An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. (2009, methodology): “In many studies, the method for scoring asthma control days has been lengthened to periods of a week (33, 52, 221) or several weeks (52, 227), referred to as ‘‘well-controlled weeks’’ or as a period of ‘‘well-controlled’’ asthma or ‘‘total control’’ (52, 227).”